A5077056822- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Thyroid Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Glutathione Transferases and Polymorphisms
- RNA modifications and cancer
- Cancer therapeutics and mechanisms
- Advanced Breast Cancer Therapies
- Ferroptosis and cancer prognosis
- Cancer-related Molecular Pathways
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Genetic factors in colorectal cancer
- Liver Disease Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Liver Disease and Transplantation
- Multiple Myeloma Research and Treatments
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
McMaster University
2023-2024
Loxo Oncology at Lilly (United States)
2019-2024
Eli Lilly (United States)
2019-2022
Presbyterian Hospital
2016
New York Hospital Queens
2016
NewYork–Presbyterian Hospital
2016
Cornell University
2016
Weill Cornell Medicine
2016
Duke Medical Center
2008
RET mutations occur in 70% of medullary thyroid cancers, and fusions rarely other cancers. In patients with RET-altered the efficacy safety selective inhibition are unknown.
Abstract Purpose: We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in United States for fusion-positive non–small cell lung cancers (NSCLC). Patients Methods: In global phase 1/2 LIBRETTO-001 trial (NCT03157128) advanced RET-altered solid tumors, selpercatinib was dosed orally (160 mg twice every day) 28-day cycles. with baseline metastases had MRI/CT scans 8 weeks 1 year (12 thereafter). this pre-planned analysis patients NSCLC...
The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize molecular determinants response resistance. We find that pre-treatment genomic landscape does not shape variability treatment except for rare instances RAS-mediated primary By contrast, acquired resistance driven by MAPK pathway reactivation one two distinct routes. In some patients, on- off-target via secondary solvent front mutations or MET amplifications...
Abstract Purpose: The RET proto-oncogene encodes a receptor tyrosine kinase that is activated by gene fusion in 1%–2% of non–small cell lung cancers (NSCLC) and rarely other cancer types. Selpercatinib highly selective inhibitor has recently been approved the FDA thyroid with activating fusions mutations. Molecular mechanisms acquired resistance to selpercatinib are poorly understood. Patients Methods: We studied patients treated on first-in-human clinical trial (NCT03157129) who were found...
Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC); however, a multicenter cohort of patients cancers treated osimertinib and selpercatinib for fusion-mediated has not previously published.
Immune checkpoint inhibitor (ICI) therapy has been found to increase the risk/severity of immune-mediated adverse events with subsequent kinase treatment in oncogenically driven cancers. We explored risk for hypersensitivity selpercatinib, a first-in-class highly selective and potent, central nervous system-active RET inhibitor, prior ICI-treated patients fusion-positive NSCLC compared their ICI-naive counterparts.
Abstract Background Abnormal liver function is a common manifestation of human disease and may also occur in approved investigational medications as drug-induced injury (DILI). Capillary blood collection devices allow for more frequent convenient measurement outside the clinic. Validation such approaches lacking. Methods This prospective, biospecimens study evaluated Tasso+ patients with abnormal tests (NCT05259618). The primary objective was to define concordance alanine aminotransferase...
Background: Anaplastic thyroid carcinoma (ATC) remains one of the most challenging malignancies to treat in modern era. Most patients present with or develop recurrent/metastatic incurable disease poor response rates conventional chemotherapy, and life expectancy is short. Next-generation sequencing (NGS) can be leveraged ATC identify oncogenic alterations that targeted molecularly specific therapy, offering new effective treatment options a subset patients. Patient Findings: A 73-year-old...
There is an overall paucity of literature on the radiologic education emergency medicine (EM) clinicians. Given fact that many EM clinicians preliminarily review images for their patients, we hypothesized a brief imaging curriculum could be efficacious in teaching basic and relevant interpretation.We designed 4-hour "radiology boot camp" group 20 residents (from all years training) covering several subject specific e-learning modules. They completed precourse postcourse quizzes to evaluate...
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease-related diarrhea, primarily because non-RET kinase inhibition. We report diarrhea and other patient-reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients RET-mutant MTC in the ongoing, phase I/II LIBRETTO-001 trial. Materials Methods Instrument completion time points were baseline (cycle 1, day 1) approximately every...
3594 Background: Selpercatinib (LOXO-292) is a highly selective and potent small molecule RET kinase inhibitor. Here we report an update on the efficacy safety of selpercatinib in RET-mutant medullary thyroid cancer (MTC). Methods: Patients with MTC were enrolled to Phase 1/2 LIBRETTO-001 trial (NCT03157128), global, multicenter (16 countries, 89 sites). Following 1 dose escalation portion trial, patients received recommended 160 mg orally twice daily. Each cycle was 28 days. The primary...
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R malignancies (NCT03740529). Pirtobrutinib was investigated 127 at least one prior BTKi therapy absence progressive disease. most common adverse event (AE) leading discontinuation cardiac disorders (n=40, 31.5%),...
First Page
LIBRETTO-001 is an ongoing, global, open-label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient-reported outcomes RET fusion-positive non-small cell lung cancer (NSCLC).Patients completed the European Organization for Research and Treatment Cancer Quality Life Questionnaire (QLQ-C30) version 3.0 at baseline (cycle 1, day 1), approximately every other 28-day cycle until 13, 12 weeks thereafter. Data were evaluated through 13 as...
<div>Abstract<p>Purpose: Acquired RET fusions have been reported at resistance to treatment with EGFR inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC), however, a multicenter cohort of patients cancers treated osimertinib and selpercatinib for fusion-mediated has not previously published. Patients methods: who received combination on prospective expanded access clinical trial (NCT03906331) single-patient compassionate use programs across five countries were centrally...
<p>Patient Cohort Identification</p>
<p>Durable combination therapy benefit</p>